Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Hold at StockNews.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Thursday.

A number of other equities analysts have also recently issued reports on ARWR. B. Riley restated a "buy" rating and issued a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Citigroup cut their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $42.13.

Arrowhead Pharmaceuticals Trading Down 1.8%

Arrowhead Pharmaceuticals stock traded down $0.28 during trading hours on Thursday, reaching $15.03. The company had a trading volume of 195,224 shares, compared to its average volume of 1,932,001. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The company has a 50-day moving average price of $13.33 and a 200 day moving average price of $17.73. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -2.91 and a beta of 0.89. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the prior year, the business posted ($1.02) EPS. Equities analysts forecast that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 40,322 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total value of $406,042.54. Following the sale, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at approximately $40,502,093.85. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 275,880 shares of company stock worth $4,034,037. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $38,000. GAMMA Investing LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $49,000. Van ECK Associates Corp increased its position in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,250 shares in the last quarter. Finally, CWM LLC raised its holdings in Arrowhead Pharmaceuticals by 134.3% in the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 2,523 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.